Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cidofovir gel for high-grade cervical intraepithelial neoplasia (COLVIR II)
NCT02976987Phase 2Completed
- Sponsor
- CHU Brugmann
- Start
- Feb 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cidofovir in cervical intraepithelial neoplasia (CIN), sponsored by CHU Brugmann. Primary endpoint: Change in biopsy conclusions (treatment success or not) at 24 months. Started Feb 2013; status: completed.
02
Drugs
cidofovir
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02976987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976987.